Novo Nordisk Stock Surges on Oral Wegovy Study Results

Novo Nordisk shares climbed 6.5% Thursday after revealing promising data for an oral version of its Wegovy weight-loss drug. The 64-week study demonstrated 16.6% average body weight reduction using 25mg daily pills—comparable to injectable results. Chief Scientific Officer Martin Holst Lange emphasized the needle-free alternative could significantly expand the drug's market potential.

The pharmaceutical breakthrough comes as demand for GLP-1 therapies continues accelerating globally. While unrelated to cryptocurrency markets, such biomedical innovations often divert speculative capital from high-growth sectors like digital assets during risk-on periods. The weight-loss drug market—projected to exceed $100 billion by 2030—represents one of several competing investment theses for growth-oriented capital.